Advantages, applications, and future directions of in vivo aptamer SELEX: A review
Molecular Therapy Nucleic Acids · 2025-09 · 36 (3) · 102575
DOI: 10.1016/j.omtn.2025.102575 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Molecular Therapy Nucleic Acids, 2025-09. Verfasst von Minchuan Lyu und 4 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Integrated Bioinformedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 00…. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 80 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: University Grants Committee.
Abstract (Originalsprache)
In vivo systematic evolution of ligands by exponential enrichment (SELEX) emerged as a transformative technique for directly identifying aptamers within living organisms. Unlike traditional in vitro methods that often fail to capture the complexity of biological interactions in physiological environments, in vivo SELEX leverages whole living organisms as selection targets. This strategy significantly enhances the specificity, functionality, and physiological relevance of the selected aptamers, making them more viable for therapeutic, diagnostic, and imaging applications. The aim of this review is to elucidate the unique advantages of in vivo SELEX compared to conventional in vitro techniques. It focuses on how in vivo SELEX improves aptamer specificity, physiological relevance, and pharmacokinetic properties, thereby enhancing their potential for use in diagnostics and therapeutics. This review highlights the principles, advancements, and challenges of in vivo SELEX, while discussing its potential to bridge the gap between aptamer discovery and clinical translation. By enabling the selection of aptamers under real physiological conditions, in vivo SELEX addresses critical limitations of in vitro methods, such as off-target effects and poor clinical translatability. The review also explores the applications of in vivo SELEX in various fields, including neurology, oncology, and cardiovascular diseases, and provides insights into future directions for optimizing this technology.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Integrated Bioinformedicine and Translational Science (IBTS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 000000, China.
- Institute of Systems Medicine and Health Sciences (SMHS), School of Chinese Medicine, Hong Kong Baptist University, Hong Kong SAR 000000, China.
- Guangdong-Hong Kong-Macao Greater Bay Area International Research Platform for Aptamer-based Translational Medicine and Drug Discovery, Hong Kong SAR 000000, China.
Förderung
- University Grants Committee
Zitieren
APA
Lyu, M., Chan, C. H., Chen, Z., Liu, Y., & Yu, Y. (2025). Advantages, applications, and future directions of in vivo aptamer SELEX: A review. Molecular Therapy Nucleic Acids, 36(3), 102575. https://doi.org/10.1016/j.omtn.2025.102575
Vancouver
Lyu M, Chan CH, Chen Z, Liu Y, Yu Y. Advantages, applications, and future directions of in vivo aptamer SELEX: A review. Molecular Therapy Nucleic Acids. 2025;36(3):102575. doi:10.1016/j.omtn.2025.102575
BibTeX
@article{Lyu2025,
author = {Lyu, Minchuan and Chan, Chi Ho and Chen, Ziqi and Liu, Yumeng and Yu, Yuanyuan},
title = {Advantages, applications, and future directions of in vivo aptamer SELEX: A review},
journal = {Molecular Therapy Nucleic Acids},
year = {2025},
volume = {36},
number = {3},
pages = {102575},
doi = {10.1016/j.omtn.2025.102575}
}
EUVIMED